Anti-tumour necrosis factor α therapy in rheumatoid arthritis: an update on safety

Ítems similars

• Serious Infection Following Anti–Tumor Necrosis Factor α Therapy in Patients With Rheumatoid Arthritis: Lessons From Interpreting Data From Observational Studies
  per: Dixon, W G, et al.
  Publicat: (2007)
• Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor α therapy: results from the British Society for Rheumatology Biologics Register
  per: Harrison, M J, et al.
  Publicat: (2008)
• Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti–tumor necrosis factor α therapy: Results from the British Society for Rheumatology Biologics Register
  per: Dixon, W G, et al.
  Publicat: (2007)
• Changes in disease characteristics and response rates among patients in the United Kingdom starting anti-tumour necrosis factor therapy for rheumatoid arthritis between 2001 and 2008
  per: Hyrich, Kimme L., et al.
  Publicat: (2011)
• Anti-tumour necrosis factor α therapy: can we afford it?
  per: Symmons, D
  Publicat: (2005)